MIPS Project Detail:
Company
Company Description:
MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular & Metabolic Diseases, and Infection and Vaccines. MedImmune is headquartered in Gaithersburg, Md., one of AstraZeneca’s three global R&D centers, with additional sites in Cambridge, UK and Mountain View, Calif.
MedImmune’s SYNAGIS therapeutic is an FDA-approved prescription injection of antibodies that is given monthly to help protect high-risk infants from severe respiratory syncytial virus, or RSV.
RSV is a common virus that, like the flu, is seasonal and easily spread. Most children will get RSV by the age of two. RSV begins with cold-like symptoms but can spread to the lungs. For babies with certain health conditions, RSV can be very serious.
SYNAGIS is the first monoclonal antibody approved for the prevention of an infectious disease, as well as the first such drug to be safely used in children.
MIPS Project
Training for Bioprocess Production
Project #
3203
|
MIPS Round
32
|
Starting Date:
Aug 2003
MIPS Project Challenge:
The goal of this project was to develop and evaluate enhanced training materials for Medlmmune’s SYNAGIS production technicians. Three, stand-alone modules explained the key elements of producing biological products and provided in-depth training as to how and why complex production steps are carried out. The training modules would assist Medlmmune in developing and maintaining a well-informed production workforce. The face-to-face training and on-demand multimedia refresher segments would help employees understand the science and engineering fundamentals that underlie the actions they take in operating the production equipment.
Project Scope:
UMD researchers used the experience gained from delivering a series of workshops to Medlmmune production technicians to design and test the first enhanced training module. This module provided basic bio production training suitable for Medlmmune personnel. Modules provided approximately 18 hours of training support material in multi-media format.
Results:
The training module developed under MIPS has been used to train MedImmune workers who manufacture Synagis®.
Principal Investigator:
Edward
Sybert
Director, Bioprocess Scale-Up Facility, University of Maryland
Project Manager:
Daniel
Pappas
Director of Cell Culture Operations
Technologies:
Chemical Engineering / Chemistry
Other
